Janux Therapeutics (JANX) said late Wednesday it priced a public offering of 5.3 million shares at $63 per share, along with pre-funded warrants for 238,095 shares at $62.999 per warrant.
The offering is expected to raise approximately $350 million in gross proceeds. The underwriters have a 30-day option to purchase up to 833,333 additional shares.
Proceeds from the offering, set to close on Friday, will support the clinical development of the company's product pipeline and general corporate purposes, Janux said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。